The effectiveness and reliability of EGFR mutation diagnostics in non-small lung cancer (NSCLC) is hindered by numerous methodological challenges, including tumour tissue accessibility, sample quality (low tumour cell content), tumour DNA quality (DNA fragmentation) and the inadequate sensitivity of molecular techniques [2, 3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.